EyePod

Eichenbaum Acorns is an editorially independent series powered by Modern Retina ® and hosted by David A. Eichenbaum, MD, FASRS, partner and director of research at Retina Vitreous Associates of Florida in Tampa. This Q&A-style article and podcast series explore the overlooked corners of the retina specialist profession through candid conversations with thought leaders. Eichenbaum is the German...

My Eyes , an Australian film created by actor, writer, and producer—and practicing optometrist—Tsu Shan Chambers, highlights the real-world challenges faced by families managing inherited eye disease and vision impairment. The Eye Care Network sat down with Chambers to discuss the film’s development and its role in raising awareness of eye health, particularly in relation to genetic conditions suc...

In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance Thompson Vision, welcomes Marguerite B. McDonald, MD, FACS, a trailblazer in refractive surgery, dry eye research, and ophthalmic leadership.  The conversation traces McDonald’s journey from childhood experiences with severe myopia to her pioneering role in laser vision correction...

Welcome to “Eichenbaum Acorns,” an editorially independent series powered by Modern Retina® and hosted by David A. Eichenbaum, MD, FASRS, partner and director of research at Retina Vitreous Associates of Florida in Tampa Bay. This series explores the overlooked corners of the retina specialist profession through candid conversations with thought leaders. Eichenbaum is the German translation for oa...

In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive strategies when performing corneal sensitivity testing in patients suspected of having neurotrophic keratitis (NK).

Glaucoma is a leading cause of irreversible blindness and affects approximately 80 million people globally, with projections to exceed .111 million by 2040.   We know that the elevated intraocular pressure is the key modifiable risk factor which is why reducing intraocular pressure is central to treatment strategies.  In this podcast, expert faculty from the featured symposium at the 2025 EnVision...

Thyroid eye disease (TED), a rare autoimmune condition, can be sight-threatening, debilitating, and disfiguring, severely impacting patients’ quality of life and daily functioning. Traditional management approaches for TED have centered on immunomodulatory therapy and surgical interventions. In January 2020, the US Food and Drug Administration (FDA) approved teprotumumab, the first therapy specifi...

Recently approved anti-VEGF agents that target additional pathways and offer innovative delivery methods with longer-lasting effects may provide advantages over older anti-VEGF agents in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this podcast, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD...

Geographic atrophy, an advanced stage of age-related macular degeneration, is a significant cause of vision loss. Given the progressive nature of geographic atrophy and its significant impact on quality of life, educating health care professionals about the disease burden, diagnostic strategies, and evolving management strategies is essential. This PER On-Air Ophthalmology Times podcast provides a...

The lacrimal functional unit, which includes the lacrimal glands and meibomian glands, can be stimulated via the trigeminal nerve to trigger production of the tear film. This approach can be used to manage dry eye disease (DED) in patients undergoing corneal refractive surgery. In this podcast, an expert explores opportunities to use this approach to treat patients with DED.

The 14th annual Glaucoma 360 conference will take place February 6 to 8, 2025, at the Westin St. Francis on Union Square in San Francisco, California. Co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, the three-day event highlights progress in glaucoma care while fostering innovation and collaboration. The conference opens on Thursday, February 6...

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-friendly, multispecialty CME ophthalmology conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times ' Sheryl Stevenson, group editorial director - eye care, to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Ric...

Robert T. Chang, MD, from Stanford University discusses the evolving role of large language models (LLMs) in glaucoma care. He explores how these AI tools, including popular systems like ChatGPT, can enhance communication and patient education by summarizing complex information and tailoring it to different literacy levels.  Chang highlights the potential of LLMs in improving efficiency in ophthal...

In this third of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we continue our discussion with Jibran Sharieff, MD, and Brandon Kingrey, MD, who are residents at the Dean McGee Eye Institute (DMEI) in Oklahoma City, Oklahoma. They recently won second place at the Eyecelerator competition held before this fall’s American Academy of Ophthalmology conference in Chic...

In this second of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we continue our discussion with Jibran Sharieff, MD, and Brandon Kingrey, MD, who are residents at the Dean McGee Eye Institute (DMEI) in Oklahoma City, Oklahoma. They recently won second place at the Eyecelerator competition held before this fall’s American Academy of Ophthalmology conference in Chi...

In this first of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we meet Jibran Sharieff, MD, and Brandon Kingrey, MD, who are residents at the Dean McGee Eye Institute (DMEI) in Oklahoma City, Oklahoma. They recently won second place at the Eyecelerator competition held prior to this month's American Academy of Ophthalmology conference in Chicago, receiving a $15,...

Take a look at a review of the highlights from Ophthalmology Times during the week of September 29, 2024. 

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss how artificial intelligence (AI) is transforming ophthalmology, especially in ocular surface disease. Dr. Periman highlights the potential of AI to streamline eye health screening and documentation, enabling ophthalmologists to focus on patients who require treatment. They emphasize how AI can enhance clinical efficiency, improve patient ou...

Take a look at a review of the highlights from Ophthalmology Times during the week of September 29, 2024. 

Take a look at a review of the highlights from Ophthalmology Times during the week of September 22, 2024. 

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias. Green outlines the status of t...

Take a look at a review of the highlights from Ophthalmology Times during the week of September 15, 2024. 

X-linked retinitis pigmentosa (XLRP) is a progressive disease that is more severe than other forms of RP. Affected male patients typically inherit a pathogenic variant of the RPGR gene on the X chromosome. In this podcast, an expert panel discusses diagnosing XLRP and provides an overview of clinical trials of gene therapies for XLRP. 

Thyroid eye disease is a condition frequently associated with Graves disease that involves both acute and chronic inflammation of the orbit. Patients may experience ocular discomfort, appearance changes, and vision loss. In this podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments. 

John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice